Janet K. Coller

ORCID: 0000-0002-8273-5048
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pharmacogenetics and Drug Metabolism
  • Drug Transport and Resistance Mechanisms
  • Oral health in cancer treatment
  • Pharmacological Effects and Toxicity Studies
  • Renal Transplantation Outcomes and Treatments
  • Immune Response and Inflammation
  • Pain Management and Opioid Use
  • Neuropeptides and Animal Physiology
  • Neutropenia and Cancer Infections
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Opioid Use Disorder Treatment
  • Inflammatory mediators and NSAID effects
  • Gut microbiota and health
  • Head and Neck Cancer Studies
  • Analytical Chemistry and Chromatography
  • Cancer therapeutics and mechanisms
  • Eicosanoids and Hypertension Pharmacology
  • Tryptophan and brain disorders
  • Neurotransmitter Receptor Influence on Behavior
  • Cancer, Stress, Anesthesia, and Immune Response
  • HIV/AIDS drug development and treatment
  • Neuroscience and Neuropharmacology Research
  • Drug-Induced Hepatotoxicity and Protection
  • Organ Transplantation Techniques and Outcomes
  • Estrogen and related hormone effects

The University of Adelaide
2014-2024

Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
2001-2013

University of Tübingen
2013

University of Otago
2013

Centre for Cancer Biology
2013

Thomas Jefferson National Accelerator Facility
2012

United States Army Medical Research and Development Command
2012

University of Copenhagen
2006

Royal Adelaide Hospital
2006

Strong epidemiological data indicate that chemotherapy-induced gut toxicity and pain occur in parallel, indicating common underlying mechanisms. We have recently outlined evidence suggesting TLR4 signaling may contribute to both side effects. therefore aimed determine if genetic deletion of improves pain. Forty-two female wild-type (WT) 42 Tlr4 null (-/-) BALB/c mice weighing between 18 25 g (10-13 weeks) received a single 270 mg/kg (i.p.) dose irinotecan hydrochloride or vehicle control...

10.1158/1535-7163.mct-15-0990 article EN Molecular Cancer Therapeutics 2016-03-30

Background and Objectives The most common treatment for opioid dependence is substitution therapy with another such as methadone. methadone dosage individualized but highly variable, program retention rates are low due in part to nonoptimal dosing resulting withdrawal symptoms further heroin craving use. Methadone a substrate the P-glycoprotein transporter, encoded by ABCB1 gene, which regulates central nervous system exposure. This retrospective study aimed investigate influence of genetic...

10.1016/j.clpt.2006.09.011 article EN Clinical Pharmacology & Therapeutics 2006-12-01

To determine the Michaelis-Menten kinetics of hydrocodone metabolism to its O- and N-demethylated products, hydromorphone norhydrocodone, individual cytochrome p450 enzymes involved, predict in vivo hepatic intrinsic clearance via these pathways.

10.1046/j.1365-2125.2003.02002.x article EN British Journal of Clinical Pharmacology 2004-02-03

Aims To investigate in a large panel of 50 human liver samples the contribution CYP2C9, CYP2D6, and CYP3A4 to overall formation potent antioestrogen Z‐4‐hydroxy‐tamoxifen, how various genotypes affect its from tamoxifen. Methods The Z‐4‐hydroxy‐tamoxifen 10 µ m tamoxifen was studied microsomes ( n =50), characterized for CYP2B6, CYP2D6 expression, CYP2B6 , CYP2C9 genotype. effect chemical monoclonal antibody inhibitors, supersomes expressing recombinant CYP isoforms also investigated....

10.1046/j.1365-2125.2002.01614.x article EN British Journal of Clinical Pharmacology 2002-08-01

Abstract The Taq I A polymorphism (A 1 ) of the dopamine D 2 receptor gene ( DRD2 ), although not a specific predictor opioid dependence, has been strongly associated with high levels prior heroin use and poor treatment outcomes among methadone maintenance patients. aims this study were to confirm these findings via retrospective analysis allele frequency in (n = 46) buprenorphine 25) patients, non‐opioid‐dependent controls 95). Subjects genotyped at locus using PCR amplification followed by...

10.1002/ajmg.b.30319 article EN American Journal of Medical Genetics Part B Neuropsychiatric Genetics 2006-03-31

BACKGROUND AND PURPOSE Emerging evidence implicates a role for toll‐like receptor 4 (TLR4) in the CNS effects of alcohol. The aim current study was to determine whether TLR4–MyD88‐dependent signalling is involved acute behavioural actions alcohol and if can activate TLR4‐downstream MAPK NF‐κB pathways. EXPERIMENTAL APPROACH TLR4 pathway evaluated using antagonist (+)‐naloxone (µ‐opioid receptor‐inactive isomer) mice with null mutations MyD88 genes. Sedation motor impairment induced by single...

10.1111/j.1476-5381.2011.01572.x article EN British Journal of Pharmacology 2011-09-29

Aims Ketamine analgesia is limited by low intrinsic efficacy compounded large interindividual variability in drug responses, possibly due to the heterogeneity concentration. The CYP2B6 * 6 allele associated with substantially reduced ketamine metabolism vitro and, therefore, may affect clearance. Our aims were examine impact of on plasma clearance and adverse effects chronic pain patients. Methods genotypes identified 49 patients who received 24 h continuous subcutaneous infusions ketamine....

10.1111/bcp.12614 article EN British Journal of Clinical Pharmacology 2015-02-23

Ketamine is primarily metabolized to norketamine by hepatic CYP2B6 and CYP3A4-mediated <i>N</i>-demethylation. However, the relative contribution from each enzyme remains controversial. The <i>CYP2B6*6</i> allele associated with reduced expression activity that may lead interindividual variability in ketamine metabolism. We examined <i>N-</i>demethylation of individual enantiomers using human liver microsomes (HLMs) genotyped for allele, insect cell–expressed recombinant CYP3A4 enzymes,...

10.1124/dmd.113.051631 article EN Drug Metabolism and Disposition 2013-04-02

Abstract We have previously shown increased intestinal permeability, to 4-kDa FITC-dextran, in BALB/c mice treated with irinotecan. Importantly, genetic deletion of Toll-like receptor 4 (TLR4; Tlr4−/−) protected against loss barrier function, indicating that TLR4 is critical tight junction regulation. The current study aimed (i) determine the molecular characteristics junctions wild-type and Tlr4−/− (ii) characterize secretory profile distal colon. Forty-two female 42 weighing between 18 25...

10.1158/1535-7163.mct-16-0330 article EN Molecular Cancer Therapeutics 2016-08-23

The role of CYP pharmacogenetics in the bioactivation cyclophosphamide is still controversial. Recent clinical studies have suggested a for either CYP2C19 or CYP2B6. aim this study was to clarify these pharmacogenes.We used combined vitro-in vivo approach determine pharmacogenes prodrug 4-hydroxy (4-OHCP). Cyclophosphamide metabolism determined human liver biobank (n= 14) and patients receiving drug treatment lupus nephritis 16)In livers known CYP2B6 genotype protein expression we observed...

10.1111/j.1365-2125.2010.03789.x article EN British Journal of Clinical Pharmacology 2010-08-31

Genetic variability in ABCB1, encoding the P-glycoprotein efflux transporter, has been linked to altered methadone maintenance treatment dose requirements. However, subsequent studies have indicated that additional environmental or genetic factors may confound ABCB1 pharmacogenetics different settings. There is evidence OPRM1, mu opioid receptor, and interact affect morphine response opposite ways. This study aimed examine whether a similar gene-gene interaction occurs for...

10.2147/pgpm.s29272 article EN cc-by-nc Pharmacogenomics and Personalized Medicine 2012-04-01

Given the evidence from retrospective studies indicating that alcohol-dependent patients with homozygous or heterozygous A118G variant of μ-opioid receptor, OPRM1, gene have significantly better outcomes when treated naltrexone; this study examined prospectively in 100 participants prescribed naltrexone for 12 weeks and offered six sessions cognitive-behavioral therapy intervention. Comparisons were made among OPRM1 genotypic groups on several outcome measures. Naltrexone treatment produced...

10.1097/fpc.0b013e32834c5445 article EN Pharmacogenetics and Genomics 2011-10-04

Tacrolimus (TAC) is a first-line immunosuppressant used to prevent organ rejection after kidney transplantation. There large inter-individual variability in its pharmacokinetics. Single nucleotide polymorphisms (SNPs) genes encoding TAC metabolizing enzymes cytochromes P450 3A4/5 (CYP3A4/5), P-glycoprotein efflux transporter (ABCB1), their expression regulator pregnane X receptor (NR1I2) and CYP3A co-factor cytochrome reductase (POR) have been studied for effects on tacrolimus disposition....

10.1111/bcpt.13016 article EN Basic & Clinical Pharmacology & Toxicology 2018-03-31

Objective To examine the association between genetic variability of IL-1B, which encodes for proinflammatory cytokine IL-1β and risk developing opioid dependence. confirm a previous study, we also examined IL-1B polymorphism alcohol Methods Genomic DNA was isolated from 60 opioid-dependent, 99 alcohol-dependent patients healthy nondependent controls. Polymerase chain reaction restriction fragment length were used to determine presence single nucleotide polymorphisms at positions -511, -31...

10.1097/fpc.0b013e328331e68f article EN Pharmacogenetics and Genomics 2009-10-21

Tacrolimus (TAC) has a narrow therapeutic index and high interindividual intraindividual pharmacokinetic variability, necessitating drug monitoring to individualize dosage. Recent evidence suggests that intragraft TAC concentrations may better predict transplant outcomes. This study aimed develop method for the quantification of in small biopsy-sized samples rat kidney liver tissue, which could be applied clinical biopsy from recipients.Kidneys livers were harvested Mrp2-deficient TR- Wistar...

10.1097/ftd.0b013e31828e8162 article EN Therapeutic Drug Monitoring 2013-08-06
Coming Soon ...